ArticleThe New England journal of medicine2017
Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.
Registry-linked trialOpen access · bronzeAbstract readCase Reports
In one paragraph
Article in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05413148 (The Effect of Wharton Jelly-derived Mesenchymal Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa), which is not on this map. Cited by 238 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
238citing papers in PubMed, 2 pooled it
51.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05413148 phase2 / phase3unknown statusnot on this mapstarted 2022, after this paper: background citation
The Effect of Wharton Jelly-derived Mesenchymal Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa
Who cites it
238 citing papers in PubMed, 2 syntheses or guidelines pooled it, 452 citations in OpenAlex.
- Stem cell therapy approaches for non-malignant diseases & non-haematological diseases in India: A systematic review.The Indian journal of medical research · 2024Pooled it
- Potential Utilisation of Secretome from Ascorbic Acid-Supplemented Stem Cells in Combating Skin Aging: Systematic Review of A Novel Idea.Cell journal · 2023Pooled it
- Efficacy of topical mesenchymal stem cell exosome in Sjögren's syndrome-related dry eye: a randomized clinical trial.BMC ophthalmology · 2025Trial
- Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy.Stem cell research & therapy · 2023Trial
- Retinal function after intravitreal injection of autologous bone marrow-derived mesenchymal stromal cells in advanced glaucoma.Documenta ophthalmologica. Advances in ophthalmology · 2021Trial
- Autologous Mesenchymal Stem Cells Improve Motor Recovery in Subacute Ischemic Stroke: a Randomized Clinical Trial.Translational stroke research · 2020Trial
- Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration.Ophthalmology · 2018Trial
- In Vivo Direct Reprogramming: Current Progress and Future Prospects from Mechanisms to Therapeutic Application.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Modalities of vision restoration in optic neuropathies and retinal disease.Progress in retinal and eye research · 2026Review
- Mesenchymal-derived neural progenitors underlie localbioRxiv : the preprint server for biology · 2026Article
- Role of stem cells in ocular diseases: Progress and challenges.Journal of biomedical research · 2026Article
- Metabolomic Profiling of Vitreous Humor Reveals Distinct Metabolic Signatures in Proliferative Vitreoretinopathy.Investigative ophthalmology & visual science · 2026Article
- Cell and Gene Therapy in Equine Ocular Disease.Veterinary ophthalmology · 2026Review
- The global regulatory landscape of stem cell medical aesthetics: challenges, comparisons, and pathways to coordination.Stem cells translational medicine · 2026Review
- Review
- Randomized Study of Intravitreal Autologous CD34+ Stem Cells in Central Retinal Vein Occlusion (Treatment of Retinal vein occlusion Using STem cells [TRUST] Report 1): Safety and Feasibility.Ophthalmology science · 2026Article
- Innate Immune-Cloaked Microgel-Coated Mesenchymal Stromal Cells Reverse Persistent Pulmonary Fibrosis via Reparative Macrophages.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- A New Vision for Ocular Disease: Stem Cell Strategies in Regenerative Ophthalmology.Stem cell reviews and reports · 2026Review
- Cell Free Regenerative Extracellular Vesicle Therapy for Ocular Diseases.Current eye research · 2025Review
- Extracellular vesicles in preeclampsia: drivers of vascular dysfunction and inflammation.American journal of physiology. Heart and circulatory physiology · 2025Review
178 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Ajay E KuriyanFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (A.E.K., T.A.A., J.H.T., M.R., P.J.R., H.W.F.), and the Center for Sight, Sarasota (M.B.P.) - both in Florida; the Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY (A.E.K.); the Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City (H.K.P., R.E.L.); and the Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA (J.L.G.).
Thomas A AlbiniFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (A.E.K., T.A.A., J.H.T., M.R., P.J.R., H.W.F.), and the Center for Sight, Sarasota (M.B.P.) - both in Florida; the Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY (A.E.K.); the Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City (H.K.P., R.E.L.); and the Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA (J.L.G.).
Justin H TownsendFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (A.E.K., T.A.A., J.H.T., M.R., P.J.R., H.W.F.), and the Center for Sight, Sarasota (M.B.P.) - both in Florida; the Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY (A.E.K.); the Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City (H.K.P., R.E.L.); and the Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA (J.L.G.).
Marianeli RodriguezFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (A.E.K., T.A.A., J.H.T., M.R., P.J.R., H.W.F.), and the Center for Sight, Sarasota (M.B.P.) - both in Florida; the Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY (A.E.K.); the Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City (H.K.P., R.E.L.); and the Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA (J.L.G.).
Hemang K PandyaFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (A.E.K., T.A.A., J.H.T., M.R., P.J.R., H.W.F.), and the Center for Sight, Sarasota (M.B.P.) - both in Florida; the Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY (A.E.K.); the Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City (H.K.P., R.E.L.); and the Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA (J.L.G.).
Robert E LeonardFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (A.E.K., T.A.A., J.H.T., M.R., P.J.R., H.W.F.), and the Center for Sight, Sarasota (M.B.P.) - both in Florida; the Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY (A.E.K.); the Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City (H.K.P., R.E.L.); and the Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA (J.L.G.).
M Brandon ParrottFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (A.E.K., T.A.A., J.H.T., M.R., P.J.R., H.W.F.), and the Center for Sight, Sarasota (M.B.P.) - both in Florida; the Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY (A.E.K.); the Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City (H.K.P., R.E.L.); and the Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA (J.L.G.).
Philip J RosenfeldFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (A.E.K., T.A.A., J.H.T., M.R., P.J.R., H.W.F.), and the Center for Sight, Sarasota (M.B.P.) - both in Florida; the Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY (A.E.K.); the Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City (H.K.P., R.E.L.); and the Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA (J.L.G.).
Harry W FlynnFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (A.E.K., T.A.A., J.H.T., M.R., P.J.R., H.W.F.), and the Center for Sight, Sarasota (M.B.P.) - both in Florida; the Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY (A.E.K.); the Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City (H.K.P., R.E.L.); and the Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA (J.L.G.).
Jeffrey L GoldbergFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (A.E.K., T.A.A., J.H.T., M.R., P.J.R., H.W.F.), and the Center for Sight, Sarasota (M.B.P.) - both in Florida; the Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY (A.E.K.); the Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City (H.K.P., R.E.L.); and the Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA (J.L.G.).
University of Miami · USDean McGee Eye Institute · USStanford University · US
Funding
Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Victor L Perez · 2004 to 2026
$12.2MNEI NIH HHS P30 EY014801
Abstract
Adipose tissue-derived "stem cells" have been increasingly used by "stem-cell clinics" in the United States and elsewhere to treat a variety of disorders. We evaluated three patients in whom severe bilateral visual loss developed after they received intravitreal injections of autologous adipose tissue-derived "stem cells" at one such clinic in the United States. In these three patients, the last documented visual acuity on the Snellen eye chart before the injection ranged from 20/30 to 20/200. The patients' severe visual loss after the injection was associated with ocular hypertension, hemorrhagic retinopathy, vitreous hemorrhage, combined traction and rhegmatogenous retinal detachment, or lens dislocation. After 1 year, the patients' visual acuity ranged from 20/200 to no light perception.
Indexed as
Adipose TissueAgedAged, 80 and overBlindnessFemaleHumansInjectionsMacular DegenerationRetinal DetachmentStem Cell TransplantationTransplantation, AutologousVision DisordersVisual Acuity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05413148ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.